Tyrosine kinases as targets for cancer therapy.
By D. Krause, R. V. van Etten. New England Journal of Medicine, 2005
1,466 citations recorded by the source corpus.
Subfields: Materials Chemistry, Mechanical Engineering, Occupational Therapy
View Paper: https://www.semanticscholar.org/paper/8f6589a8f9cd28c163ca66cf1c6493befd0c4f16
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Materials Chemistry
In Mechanical Engineering
In Occupational Therapy
Citations in the corpus
- Chromosome aberrations in solid tumors (2003, background): “, and Gleevec is approved for the treatment of chronic myeloid leukemia and shows activity against gastrointestinal stromal tumor”
- The delivery of therapeutic oligonucleotides (2016, background): “However, there are many high affinity monoclonal antibodies for RTK external domains (107) that can be used as targeting reagents, converted to Fab fragments, or reconfigured as scFv reagents (108).”
- Assessment of the Evolution of Cancer Treatment Therapies (2011, background): “The current pharmacological trend has been to develop kinase inhibitors [20,21].”
- Epidermal growth factor receptor mutations in lung cancer (2007, background): “The deregulation of EGFR in NSCLC The receptor tyrosine kinase (RTK) super-family of cell-surface receptors serve as mediators of cell signalling by extra-cellular growth factor”
- CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? (2011, background): “In addition, CD44v6 binding to the ECM also activates the PI3K–Akt pathwa”
- Cyclin D as a therapeutic target in cancer (2011, background): “Given the increasingly routine clinical use of specific kinase inhibitor”
- A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. (2006, critical): “It is increasingly clear, however, that many highly selective kinase inhibitors are displaying limited efficacy in clinical trials, despite the fact that their targets have been extensively validated to promote tumor progression (Krause and Van Etten, 2005).”
- Comparing antibody and small-molecule therapies for cancer (2006, background): “Small-molecule agents for cancer therapy RTKs and non-RTKs are crucial mediators in signalling pathways of cell proliferation, differentiation, migration, angiogenesis, cell-cycle regulation and other”
- Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study (2011, background): “Moreover, a low to moderate fraction of major targetable kinases—including PIK3CA, EGFR (epidermal growth factor receptor), and ERBB2—may be aberrant in several cancers (12, 13).”
- Pathway-based personalized analysis of cancer (2013, background): “…factor 2-α pathway); many are known key players in glioblastoma and cancer, have a prognostic value, and are promising drug targets [such as MAP kinase (22, 23), Insulin signaling and its components (24), RET tyrosine kinase (25), EGFR/ERBB signaling (26), PDGF signaling (27), and integrins (28)].”
- Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition (2007, background): “These agents fall into two general classes: humanized monoclonal antibodies directed against receptor tyrosine kinases or their ligands, and small-molecule TKI”